Survivin: a novel regulator of intimal hyperplasia and vein graft remodeling

Survivin：内膜增生和静脉移植重塑的新型调节剂

• 批准号: 7318102
• 负责人: Michael S Conte
• 金额: $ 40.56万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7318102
• 关键词: Amputation; Angioplasty; Apoptosis; Apoptotic; Arterial Injury; Arteries; Atherosclerosis; Attenuated; Balloon Angioplasty; Binding; Blood Vessels; Bypass; Cardiovascular Diseases; Cardiovascular system; Cell Cycle; Cell Cycle Progression; Cell Survival; Cells; Client; Coronary; Data; Development; Disease; Embryonic Development; Engineering; Failure; Gene Expression; Genes; Genetic; Goals; Growth; Healed; Heat Losses; Heat-Shock Proteins 90; Human; Hyperplasia; In Vitro; Injury; Intervention; Lesion; Life; Limb structure; Malignant Neoplasms; Mitosis; Modeling; Molecular; Molecular Chaperones; Molecular Target; Normal tissue morphology; Operative Surgical Procedures; Oryctolagus cuniculus; Oxidoreductase; Paracrine Communication; Pathway interactions; Patients; Peptides; Peripheral; Pharmaceutical Preparations; Phenotype; Play; Prevention; Process; Proliferating; Proteins; Proteomics; Quality of life; RNA Interference; Rate; Regulation; Research Personnel; Research Proposals; Resistance; Role; Signal Pathway; Signal Transduction; Smooth Muscle Myocytes; Testing; Therapeutic; Time; Translational Research; United States; Vascular remodeling; Veins; artery occlusion; atheroprotective; base; cell growth; clinical efficacy; clinically relevant; design; graft failure; healing; improved; in vivo; inhibitor-of-apoptosis protein; inhibitor/antagonist; interest; mortality; neoplastic; neoplastic cell; novel; novel strategies; peptide analog; protein protein interaction; research study; response; response to injury; restenosis; survivin; therapeutic target

DESCRIPTION (provided by applicant): Failure of vascular interventions, including angioplasty, stenting, and bypass surgery, frequently results from an exaggerated healing response in the vessel wall, leading to narrowing and occlusion. This process is characterized by the formation of intimal hyperplasia (IH), a lesion consisting primarily of smooth muscle cells (SMC) bearing a proliferative, synthetic, and de-differentiated phenotype. Recent evidence suggests that survivin (SW), a novel protein which regulates both apoptosis and proliferation, may be an important therapeutic target in disorders characterized by deregulated growth, such as cancer and IH. In this translational research proposal we seek to validate SW as a molecular target in IH, most particularly in the context of vein graft failure. First we will investigate approaches to directly inhibit SW gene expression, in- vitro and in-vivo. The effects of SW knockdown on SMC phenotype and vein graft hyperplasia will be determined. In the second specific aim, we will explore the therapeutic relevance of the interaction between SW and heat shock protein 90 (HspQO), a molecular chaperone, using a peptide-based approach to disrupt this critical protein-protein interaction. Finally in the third aim we will investigate whether anti-SW molecular strategies may sensitize vascular SMC to the pro-apoptotic effects of statin drugs, potentially expanding the therapeutic utility of these atheroprotective drugs to extend the benefits of vascular interventions. Vein bypass surgery, currently employed in some 500,000 cases annually in the United States, is a critical life- or limb-sparing intervention for many patients afflicted with cardiovascular disease. Although often effective, vein bypass grafts are subject to a significant rate of failure over time (30- 50% within five years), leading directly to mortality, limb amputation and diminished quality of life. This proposal seeks to broaden the understanding of factors which are involved in vein graft failure, and will examine a novel approach to re- engineer bypass grafts that may be resistant to occlusion. These studies also have direct relevance for improving the long term results of other cardiovascular interventions such as percutaneous angioplasty and stenting, by providing new molecular approaches to control the vascular injury response.

描述(由申请人提供)：血管介入治疗的失败，包括血管成形术、支架植入和搭桥手术，通常是由于血管壁的过度愈合反应，导致狭窄和闭塞。这一过程的特征是形成内膜增生(IH)，这是一种主要由具有增殖、合成和去分化表型的平滑肌细胞(SMC)组成的病变。最近的证据表明，Survivin(Sw，Survivin，Sw)是一种同时调节细胞凋亡和增殖的新蛋白，可能是肿瘤和IH等以非调控生长为特征的疾病的重要治疗靶点。在这项转化性研究中，我们试图验证Sw作为IH的分子靶点，尤其是在静脉移植失败的情况下。首先，我们将研究在体外和体内直接抑制sw基因表达的方法。Sw基因敲除对SMC表型和静脉移植物增生的影响将被确定。在第二个特定目标中，我们将使用基于多肽的方法来破坏这一关键的蛋白质-蛋白质相互作用，以探索Sw与热休克蛋白90(HspQO)之间的相互作用的治疗相关性。最后，在第三个目标中，我们将研究抗SW分子策略是否可以使血管SMC对他汀类药物的促凋亡作用敏感，从而潜在地扩大这些动脉粥样硬化保护药物的治疗作用，从而延长血管干预的益处。静脉搭桥手术目前在美国每年约有50万例患者使用，对于许多患有心血管疾病的患者来说，这是一种关键的保命或保肢干预措施。静脉搭桥术虽然通常有效，但随着时间的推移，失败率很高(五年内为30%-50%)，直接导致死亡、肢体截肢和生活质量下降。这项建议旨在扩大对静脉移植失败相关因素的理解，并将研究一种新的方法来重新设计可能抵抗闭塞的搭桥。这些研究还提供了控制血管损伤反应的新的分子方法，对于改善其他心血管干预措施的长期效果也有直接关系，例如经皮血管成形术和支架置入术。